Document is current
Any future updates will be listed below
-
Authors
Fenerich, Bruna Alves
Fernandes, Jaqueline Cristina
Rodrigues Alves, Ana Paula Nunes
Coelho-Silva, Juan Luiz
Scopim-Ribeiro, Renata
Scheucher, Priscila Santos
Eide, Christopher A.
Tognon, Cristina E.
Druker, Brian J. http://orcid.org/0000-0001-8331-8206
Rego, Eduardo Magalhães
Machado-Neto, João Agostinho
Traina, Fabiola http://orcid.org/0000-0003-4258-289X
- License Information
-
More Information
Article History
Received: 22 March 2019
Revised: 15 November 2019
Accepted: 24 November 2019
First Online: 24 January 2020
Competing interests
: B.J.D. potential competing interests are as follows—SAB: Aileron Therapeutics, ALLCRON, Cepheid, Gilead Sciences, Vivid Biosciences, and Celgene & Baxalta (inactive); SAB and stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, GRAIL, Third Coast Therapeutics, and CTI BioPharma (inactive); scientific founder and stock: MolecularMD; board of directors and stock: Amgen; board of directors: Burroughs Wellcome Fund, CureOne; joint steering committee: Beat AML LLS; clinical trial funding: Novartis, Bristol-Myers Squibb, and Pfizer; royalties from patent 6958335 (Novartis exclusive license HSU) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license). Other authors declare no potential conflicts of interest.
: This research was approved by the Research Ethics Committee in Human Research at Ribeirão Preto General Hospital and Ribeirão Preto Medical School (CEP HCRP and FMRP); written informed consent was obtained from all subjects, and the study was performed in accordance with the Declaration of Helsinki.
